Physiomics Regulatory News (PYC)

4 October 2022

Physiomics plc

("Physiomics") or ("the Company")

Contract award

Physiomics plc (AIM: PYC), the consultancy using mathematical models to support the development of drug treatment regimens and personalised medicine solutions, is pleased to announce that it has been awarded a third contract by existing client, Numab Therapeutics ("Numab"). Physiomics will use its PKPD modelling capabilities to support the translation of pre-clinical to clinical data with a focus on dose selection. The project is expected to be completed between now and the end of the calendar year.

Physiomics CEO, Dr Jim Millen, commented: "We are pleased to continue our collaboration with Numab and to have been selected to continue to support the development of their multispecific antibody-based therapeutics."

Enquiries:

Physiomics plc

Dr Jim Millen, CEO

+44 (0)1865 784 980

Hybridan LLP (broker)

Claire Louise Noyce

+44 (0) 203 764 2341

Strand Hanson Ltd (NOMAD)

James Dance & James Bellman

+44 (0)20 7409 3494

Notes to Editor

About Physiomics

Physiomics plc (AIM: PYC) is an oncology consultancy using mathematical models to support the development of cancer treatment regimens and personalised medicine solutions. The Company's Virtual Tumour™ technology uses computer modelling to predict the effects of cancer drugs and treatments to improve the success rate of drug discovery and development projects while reducing time and cost. The predictive capability of Physiomics' technologies have been confirmed by over 90 projects, involving over 40 targets and 70 drugs, and has worked with clients such as Merck KGaA, Astellas, Merck & Co and Bicycle Therapeutics.